Tesaro Inc. (NASDAQ:TSRO) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $97.90 and last traded at $97.08, with a volume of 164,841 shares changing hands. The stock had previously closed at $96.36.

A number of research analysts have issued reports on the stock. RBC Capital Markets assumed coverage on shares of Tesaro in a research report on Friday. They set an “outperform” rating and a $122.00 price objective on the stock. Royal Bank Of Canada assumed coverage on shares of Tesaro in a research report on Friday. They set an “outperform” rating and a $122.00 price objective on the stock. Citigroup Inc. boosted their price objective on shares of Tesaro from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, August 8th. Credit Suisse Group AG reissued a “buy” rating on shares of Tesaro in a research report on Friday, August 5th. Finally, Jefferies Group set a $80.00 price objective on shares of Tesaro and gave the company a “hold” rating in a research report on Friday, August 5th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $85.50.

The stock’s market cap is $4.96 billion. The company’s 50 day moving average is $87.41 and its 200 day moving average is $53.77.

Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.43. During the same quarter last year, the business posted ($1.51) earnings per share. The business had revenue of $36.60 million for the quarter, compared to the consensus estimate of $4.98 million. On average, analysts predict that Tesaro Inc. will post ($7.31) earnings per share for the current fiscal year.

In other news, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the sale, the vice president now directly owns 12,500 shares in the company, valued at $929,375. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction on Friday, June 10th. The stock was sold at an average price of $40.75, for a total value of $285,250.00. Following the sale, the vice president now owns 3,500 shares of the company’s stock, valued at $142,625. The disclosure for this sale can be found here.

Several hedge funds have added to or reduced their stakes in TSRO. Rhumbline Advisers increased its stake in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares during the period. Mutual of America Capital Management LLC increased its stake in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock valued at $2,068,000 after buying an additional 19,320 shares during the period. Bank of Montreal Can increased its stake in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares during the period. Finally, Jennison Associates LLC increased its stake in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares during the period.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.